Cyclic pyranopterin monophosphate

Drug Profile

Cyclic pyranopterin monophosphate

Alternative Names: ALXN-1101; cPMP; cPMP-cpd

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphatec Pharmaceuticals
  • Developer Alexion Pharmaceuticals
  • Class Organophosphorus compounds; Pterins
  • Mechanism of Action Molybdenum cofactor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Molybdenum cofactor deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Molybdenum cofactor deficiency

Most Recent Events

  • 27 Jul 2017 Cyclic pyranopterin monophosphate is available for licensing as of 27 Jul 2017.
  • 27 Oct 2016 Alexion initiates enrolment in a phase II/III trial for Molybdenum-cofactor deficiency (In neonates) in USA, Israel, Spain, Germany and United Kingdom
  • 03 Feb 2016 Phase-II/III clinical trials in Molybdenum-cofactor deficiency (In neonates) in Germany, United Kingdom, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top